Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M. Marmarelis
P1.01-64 Impact of STK11 Co-Mutation on Outcomes Following Immunotherapy Among Patients With TP53 and KRAS Mutated Stage IV NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
MA19.10 Impact of STK11/LKB1 Genomic Alterations on Clinical Outcomes With Chemo-Immunotherapy in Non-Squamous NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P021 the Impact of TP53 Mutation and Tumor Mutation Number on Outcomes in Patients With Stage I Non Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-28 Impact of Afatinib Dosing on Safety and Efficacy Real-World in Patients With EGFR Mutation-Positive Advanced NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Relationships Between KRAS Mutation Status and Baseline Radiographic Distribution of Disease in Patients With Stage IV Colorectal Cancer
Abdominal Imaging
P2.13-26 Impact of Concurrent Tumor Suppressor Gene Mutation on Clinical Outcomes in EGFR Mutated NSCLC Treated With First-Line TKI
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Impact of Unfavorable Factors on Outcomes Among Inoperable Stage II-IV Non–Small Cell Lung Cancer Patients Treated With Proton Therapy
International Journal of Radiation Oncology Biology Physics
Oncology
Radiology
Cancer Research
Radiation
Nuclear Medicine
Imaging
P061 Real Clinical Practice of Using Immunotherapy in NSCLC Patients With EGFR Mutation
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-42 Real-World Evaluation of Tolerability in Older Adult Patients (≥75 Years Old) With EGFR-mutated NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Impact of TP53 Mutations on Outcome in EGFR -Mutated Patients Treated With First-Line Tyrosine Kinase Inhibitors
Clinical Cancer Research
Cancer Research
Oncology